Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes

Abstract

In this population, with thorough screening and careful post-gene transfer management, replacement therapy with onasemnogene abeparvovec-xioi is safe and shows promise for early efficacy.